Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics (Nasdaq: FHTX) has elected Dr. Thomas Lynch Jr. to its Board of Directors. Dr. Lynch, president of Fred Hutchinson Cancer Center and former Chief Scientific Officer at Bristol-Myers Squibb, brings extensive scientific and clinical expertise to the role. His appointment comes as Foghorn progresses clinical trials for drug candidates FHD-609 and FHD-286. CEO Adrian Gottschalk emphasized the value of Dr. Lynch's experience in guiding the company's growth. This leadership addition could enhance Foghorn’s capabilities in drug development and strengthen its mission to address serious diseases.

Foghorn Therapeutics (FHTX) presented promising initial Phase 1 data highlighting the degradation of BRD9 in metastatic tumor biopsies of synovial sarcoma using FHD-609. This investigational drug demonstrates strong selectivity and efficacy, potentially leading to significant tumor growth inhibition. The company also introduced a new protein degrader program targeting EP300 mutations, which could benefit over 100,000 patients annually. The data reinforces Foghorn's status as a leader in protein degradation therapies, with further detailed results expected in 2023.

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the 5th Annual Targeted Protein Degradation Summit from October 25-28, 2022, in Danvers, Massachusetts. The company will present initial pharmacodynamic data from its Phase 1 study of FHD-609, a selective degrader of BRD9 for treating synovial sarcoma and SMARCB1-loss tumors. Notable sessions include a keynote by Danette L. Daniels, Ph.D., on October 26, and a workshop on preclinical study design on October 25. Foghorn is advancing its protein degradation platform amid ongoing clinical studies.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotech firm, will participate in the Bank of America 2022 Precision Oncology Conference on October 3, 2022, at 12:20 p.m. ET. The company's innovative Gene Traffic Control platform aims to address gene expression issues in serious diseases, with a primary focus on oncology. A webcast of the event will be available on their website for 90 days post-event. Foghorn is developing several oncology product candidates, with two currently in clinical trials.

Foghorn Therapeutics (Nasdaq: FHTX) has announced management's participation in key investor conferences this September. The biotechnology company focuses on developing innovative treatments by correcting abnormal gene expression, particularly in oncology. The upcoming conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 13. Webcasts of these events will be available on their website for 90 days post-conference.

Foghorn Therapeutics has announced the appointment of co-founder Cigall Kadoch as an Investigator for the Howard Hughes Medical Institute (HHMI), effective September 6, 2022. Following this appointment, Dr. Kadoch has resigned from her position on Foghorn’s Board of Directors but will continue as a Scientific Advisor to the Board. CEO Adrian Gottschalk praised her contributions, emphasizing her leadership in chromatin regulation research. Foghorn continues to focus on developing innovative therapies for serious diseases through its Gene Traffic Control platform.

Foghorn Therapeutics (Nasdaq: FHTX) announced a full clinical hold by the FDA on the Phase 1 study of its drug FHD-286 for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This decision arose from reports of additional suspected fatal differentiation syndrome cases linked to FHD-286. Meanwhile, the study for metastatic uveal melanoma is proceeding as planned, with data expected in early 2023. Foghorn remains committed to addressing FDA concerns to lift the hold promptly.

Foghorn Therapeutics (Nasdaq: FHTX) announced the election of B. Lynne Parshall to its Board as the Chair of the Audit Committee. With nearly 30 years in biotechnology and experience at Ionis Pharmaceuticals, her leadership is expected to bolster Foghorn's growth. CEO Adrian Gottschalk emphasized that her track record in therapy development will be pivotal as the company works towards its vision of a fully-integrated biotech. Parshall will play a crucial role in advancing key clinical programs, including FHD-286 and FHD-609.

Foghorn Therapeutics (FHTX) provided a corporate and financial update for Q2 2022. The Phase 1 study of FHD-286 in metastatic uveal melanoma is progressing, while a partial clinical hold by the FDA affects its use in AML and MDS. Initial clinical data for FHD-609 in synovial sarcoma is expected in 2023. The company achieved a research milestone under its Merck collaboration, triggering a $5 million payment. As of June 30, 2022, Foghorn reported $394.7 million in cash and equivalents, indicating strong financial health.